Product Image

Contributor Information

  • Institute A*STAR Accelerate Technologies Pte Ltd

Tool Details

  • Tool name: Anti-LYPD3 [11F1]
  • Clone: 11F1
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IF
  • Description: LYPD3 (Ly6/PLAUR domain-containing protein 3) also known as C4.4A, is a structural homologue of the urokinase receptor, uPAR, which constitutes a well-established prognostic marker in various human cancers. It consists of 346 amino acids and is glycosylphosphatidylinositol (GPI)-anchored, and its extracellular domains are composed of two modules belonging to the Ly6/uPAR/Î?-neurotoxin (LU) protein domain family. LYPD3 is endogenously expressed in suprabasal cells of squamous epithelia and amnion membrane in human placenta. Currently, LYPD3 has no defined functions but inhibition of tumor cell migration with anti-LYPD3 antibody suggests its role in cell/cell, cell/matrix interaction and tumour invasion and metastasis.
  • Immunogen: GST-LYPD3 (residues 31 to 326) fusion protein
  • Isotype: IgG1
  • Research area: Cell biology
  • Myeloma used: Sp2/0-Ag14

  • For Research Use Only

Target Details

  • Target: Ly6/PLAUR domain-containing protein 3
  • Target background: LYPD3 (Ly6/PLAUR domain-containing protein 3) also known as C4.4A, is a structural homologue of the urokinase receptor, uPAR, which constitutes a well-established prognostic marker in various human cancers. It consists of 346 amino acids and is glycosylphosphatidylinositol (GPI)-anchored, and its extracellular domains are composed of two modules belonging to the Ly6/uPAR/a-neurotoxin (LU) protein domain family. LYPD3 is endogenously expressed in suprabasal cells of squamous epithelia and amnion membrane in human placenta. Currently, LYPD3 has no defined functions but inhibition of tumor cell migration with anti-LYPD3 antibody suggests its role in cell/cell, cell/matrix interaction and tumour invasion and metastasis.

Application Details

  • Application: FACS ; IF

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-FN-EDB [3F6.1]

#160457
Product Image

Anti-LY-49A [YE1/48.10.6]

#160512
Product Image

Anti-PITPb [4a7]

#151819